Sona Nanotech Inc (TSE:SONA)
:SONA
Want to see TSE:SONA full AI Analyst Report?
SONA Stock Chart & Stats
C$0.40
>-C$0.01(-2.00%)
At close: 4:00 PM EST
C$0.40
>-C$0.01(-2.00%)
Day’s Range― - ―
52-Week RangeC$0.28 - C$0.91
Previous CloseN/A
Volume36.80K
Average Volume (3M)124.26K
Market Cap
C$35.46M
Enterprise ValueC$35.74M
Total Cash (Recent Filing)C$36.55K
Total Debt (Recent Filing)C$318.31K
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Jun 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding114,375,250
10 Day Avg. Volume87,178
30 Day Avg. Volume124,263
Financial Highlights & Ratios
PEG Ratio-2.88
Price to Book (P/B)-1.80K
Price to Sales (P/S)0.00
P/FCF Ratio-35.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Gold Nanorod TechnologySona’s ownership of proprietary gold nanorod materials is a durable strategic asset: a platform technology can enable multiple diagnostic assays, licensing opportunities, and partnerships. This intellectual-property base supports long-term commercialization options beyond a single product.
Focus On Biomedical/diagnostics ApplicationsTargeting diagnostics and life‑science assay formats aligns the company with enduring market demand for improved diagnostic reagents and platforms. This focus creates multiple commercialization pathways (assay makers, labs, partners) that can generate recurring revenues if product-market fit is achieved.
Modest Absolute Debt LevelLow absolute debt reduces immediate interest and covenant pressure, preserving flexibility for financing via equity or strategic partnerships. With limited debt service needs, management can prioritize R&D and commercialization spending while seeking revenue or capital to stabilize capital structure.
Bears Say
Zero Reported RevenuePersistent zero revenue indicates the business has not achieved commercial traction. Without sales, product-market fit and sustainable business economics remain unproven, forcing ongoing reliance on external funding or partnerships to finance operations and delaying any path to self-sustaining cash flow.
Sustained Negative Cash Flow / Cash BurnFree cash flow roughly mirrors net losses, showing losses convert into cash burn rather than non-cash adjustments. This structural outflow creates persistent funding needs; absent revenue or significant capital raises, the company risks dilution, cutbacks to R&D/commercialization, or insolvency.
Negative Shareholders' Equity And Shrinking AssetsThe shift to negative equity increases financial fragility: it limits borrowing capacity, weakens creditor confidence, and raises the likelihood that future capital must be dilutive. Declining assets suggest reduced operational resources, constraining the firm’s ability to execute commercialization plans.
Sona Nanotech Inc News
SONA FAQ
What was Sona Nanotech Inc’s price range in the past 12 months?
Sona Nanotech Inc lowest stock price was C$0.28 and its highest was C$0.91 in the past 12 months.
What is Sona Nanotech Inc’s market cap?
Sona Nanotech Inc’s market cap is C$35.46M.
When is Sona Nanotech Inc’s upcoming earnings report date?
Sona Nanotech Inc’s upcoming earnings report date is Jun 25, 2026 which is in 59 days.
How were Sona Nanotech Inc’s earnings last quarter?
Currently, no data Available
Is Sona Nanotech Inc overvalued?
According to Wall Street analysts Sona Nanotech Inc’s price is currently Overvalued.
Does Sona Nanotech Inc pay dividends?
Sona Nanotech Inc does not currently pay dividends.
What is Sona Nanotech Inc’s EPS estimate?
Sona Nanotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sona Nanotech Inc have?
Sona Nanotech Inc has 114,375,250 shares outstanding.
What happened to Sona Nanotech Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sona Nanotech Inc?
Currently, no hedge funds are holding shares in TSE:SONA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sona Nanotech Inc
Sona Nanotech Inc., nanotechnology life sciences company, manufactures and sells gold nanorod products for diagnostic tests. The company also provides Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic assay for the detection of the spike protein antigen from SARS-CoV-2 in saliva specimens from individuals, who are suspected of COVID-19; Gemini gold nanorods; Omni gold nanorods for medical applications; and contract services. Its products are used in various applications, including drug delivery, food and beverage testing, environmental testing, cell imaging, cancer treatment, and liposuction therapy, as well as medical and consumer, military, and veterinary diagnostics. The company is based in Halifax, Canada.
Technical Analysis
BioMark Diagnostics
―
Eastwood Bio-Medical Canada
―
StageZero Life Sciences Ltd
―
Medmira
―
ZYUS Life Sciences
―
Options Prices
Currently, No data available
---